CALCIUM ACETATE

Post-LOE

Hikma

ANDAORALTABLET

Approved

Jan 2008

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

CALCIUM ACETATE by Hikma is acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration. Approved for serum phosphorus in patients with end stage renal disease. First approved in 2008.

Drug data last refreshed 19h ago

Mechanism of Action

acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.

Indications (1)

serum phosphorus in patients with end stage renal disease

Clinical Trials (1)

NCT00196755Phase 3Completed

Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis

Started Dec 2004

138 enrolled

Peritoneal DialysisChronic Kidney Disease

Company

Worked on CALCIUM ACETATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.